ArcticZymes Technologies ASALTS:0DRV -11.96%76 Return-on-Tangible-Equity is 0.77% as of Mar. 2026, which is 75% below its 10-year median of 3.11. GuruFocus rates LTS:0DRV with a GF Score™ of 76/100 and a GF Value™ of kr23.91 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,199 Biotechnology companies, ArcticZymes Technologies ASA ranks better than 81.48% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ArcticZymes Technologies ASA's annualized net income for the quarter that ended in Mar. 2026 was kr2.3 Mil. ArcticZymes Technologies ASA's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr305.6 Mil. Therefore, ArcticZymes Technologies ASA's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 0.77%.
The historical rank and industry rank for ArcticZymes Technologies ASA's Return-on-Tangible-Equity or its related term are showing as below:
LTS:0DRV'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -51 Med: 3.11 Max: 69.73
Current: 4.71
During the past 13 years, ArcticZymes Technologies ASA's highest Return-on-Tangible-Equity was 69.73%. The lowest was -51.00%. And the median was 3.11%.
LTS:0DRV's Return-on-Tangible-Equity is ranked better than 81.48% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs LTS:0DRV: 4.71
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ArcticZymes Technologies ASA Return-on-Tangible-Equity Related Terms
ArcticZymes Technologies ASA Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRV vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.77% mean?
ArcticZymes Technologies ASA (LTS:0DRV) has a Return-on-Tangible-Equity of 0.77% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ArcticZymes Technologies ASA and its competitors. This is 75% below median its historical median of 3.11. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #222 out of 1199 companies in the Biotechnology industry, placing it in the top 18.5%.
Is ArcticZymes Technologies ASA's Return-on-Tangible-Equity too high?
ArcticZymes Technologies ASA's current Return-on-Tangible-Equity of 0.77% is 75% below median its 10-year median of 3.11. Based on the distribution chart, ArcticZymes Technologies ASA ranks #222 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #222 out of 1199 companies for Return-on-Tangible-Equity. This places ArcticZymes Technologies ASA in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ArcticZymes Technologies ASA and its competitors. ArcticZymes Technologies ASA's current Return-on-Tangible-Equity is 0.77%, which is 75% below median its own 10-year median of 3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr23.91, compared to a current price of kr18.40 — trading 23% below its estimated fair value. The current Return-on-Tangible-Equity is 0.77%, which is 75% below median its 10-year median of 3.11. ArcticZymes Technologies ASA's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current Return-on-Tangible-Equity is 0.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr18.40 is trading 23% below its estimated GF Value™ of kr23.91.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
Return-on-Tangible-Equity: 0.77% (75% below median its 10-year median of 3.11)
GF Value™: kr23.91 vs. price of kr18.40 (23% below fair value)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
76GF Score
Get the complete analysis for LTS:0DRV
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
